Background: Signet-ring cell carcinoma (SRCC) of the urinary bladder is a rare entity. No previous studies have directly compared the cancer-specific survival of patients with SRCC to patients with urothelial carcinoma (UC) of the urinary bladder. Materials and methods: Patients with diagnosis of urinary bladder SRCC and UC were identified in the Surveillance, epidemiology, and end results program (SEER) (2001-2004). Demographic of patients and clinical characteristics at diagnosis were compared. Differences in cancer-specific survival were compared using univariate and multivariate analysis. Results: A total of 103 patients with SRCC and 14,648 patients with UC were indentified. Patients with SRCC were younger (P < 0. 001), more commonly presented with higher-grade histology (P < 0. 001) and advanced stage disease (P < 0. 001), in comparison with patients with UC. The 3-year cancer-specific survival rate was 67. 0% for patients with UC and 33. 2% for SRCC. On multivariate analysis, there was an increased mortality risk in patients with SRCC versus UC (HR 1. 49, 95% CI 1. 11-2. 00, P < 0. 01). Conclusions: Even after adjusting for demographic, surgical, and pathological factors, cancer-specific survival rate was significantly worse in patients with SRCC compared to UC. Further research into the biology of this rare tumor is required to explain these results.
- Bladder cancer
- Epidemiology and end results program (SEER) program
- Signet-ring cell carcinoma (SRCC)
- Urothelial carcinoma (UC)
ASJC Scopus subject areas